Canaccord Genuity Group Analysts Give Aurora Cannabis (TSE:ACB) a C$10.00 Price Target

Canaccord Genuity Group set a C$10.00 price objective on Aurora Cannabis (TSE:ACB) in a report released on Tuesday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

Separately, ATB Capital reduced their target price on Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating on the stock in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, Aurora Cannabis has a consensus rating of “Buy” and a consensus price target of C$9.25.

Aurora Cannabis Price Performance

ACB stock opened at C$5.67 on Tuesday. The company’s 50-day moving average price is C$6.23 and its two-hundred day moving average price is C$6.68. The firm has a market cap of C$318.91 million, a P/E ratio of -5.56 and a beta of 0.71. The company has a quick ratio of 2.48, a current ratio of 3.42 and a debt-to-equity ratio of 18.72. Aurora Cannabis has a 12 month low of C$4.95 and a 12 month high of C$9.90.

Aurora Cannabis (TSE:ACB) last issued its quarterly earnings results on Wednesday, November 5th. The company reported C($0.91) earnings per share for the quarter. The firm had revenue of C$90.37 million for the quarter. Aurora Cannabis had a negative return on equity of 8.36% and a negative net margin of 22.55%. On average, analysts anticipate that Aurora Cannabis will post -0.22 earnings per share for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.